CLOSURE-AF Explained: Does This Trial Really Change LAA Closure?

The CLOSURE-AF trial is the first randomized study suggesting worse outcomes of left atrial appendage closure (LAA closure) compared to medical therapy in high-risk atrial fibrillation patients. But what do the data actually show? In this video, Prof. Horst Sievert explains: • The design and key results of CLOSURE-AF • Why stroke rates were identical between groups • What drove the difference in the primary endpoint • How procedural risk and patient selection influenced the outcome The key question is whether CLOSURE-AF changes the role of LAA closure — or refines how it should be used. This video provides an independent clinical interpretation of the published NEJM data. For international patients and referring physicians: 👉 https://cardiovascular.global #Cardiology #LAAO #AtrialFibrillation #StructuralHeart #CLOSUREAF